Pulmonary Fibrosis 
Healthcare Professional
 Resource Library

Resources to support healthcare professionals in understanding interstitial lung disease, causes, treatments, patient experiences, fellowship and grant opportunities, and more.

Interstitial Lung Disease (ILD) Guidelines

Interstitial lung disease (ILD) is a group of pulmonary diseases characterized by inflammation and fibrosis of the lung parenchyma.1

What is Pulmonary Fibrosis?

Pulmonary Fibrosis (PF) isn’t just one disease. It is a family of more than 200 interstitial lung diseases (ILDs) that cause inflammation and/or scarring of the of the lungs. Over time, normal lung tissue is destroyed, rendering them unable to provide the body with sufficient oxygen. Although currently there is no cure, many people living with PF can be helped with the right treatment, support, and for some, lung transplantation.

ILD Research Papers

Stay current on ILD science and progress. If you’ve recently published a paper that you’d like to share, contact us here

ILD Drugs

Find the most recent monographs, patient information leaflets, and provincial resources for ILD drugs.

Patient & Caregiver Resources 

These resources are intended to help patients & caregivers better understand what PF is, the causes, symptoms, and what to expect as PF progresses. Please share these resources with your patients.

Understanding Patients & Caregivers

Personal stories and factual reports.

CPFF asked the PF community to complete surveys about their experiences living with pulmonary fibrosis, its impact on their lives, and what they needed for the future. Many people living with PF and their caregivers from across the country responded to our call. Read the reports:

Read the CPFF Breathless for Change Reports

Breathing is a fundamental right, yet many Canadians living with pulmonary fibrosis encounter challenges getting access to the home oxygen therapy they need. To understand all aspects of this issue CPFF commissioned three groundbreaking national research surveys – with patients and caregivers, medical professionals, and oxygen providers, to gain their valuable perspectives. Additionally, a collective of prominent physicians including Dr. Kerri A. Johannson (Department of Medicine, Department of Community Health Sciences, and Interstitial Lung Disease Program, University of Calgary) undertook a detailed review of the issues at hand that guide (and restrict) access to oxygen therapy for patients in need.

The Access to Oxygen Therapy in Canada Report summarizes all of the research CPFF conducted
with all stakeholder groups in 2022 and 2023. Individual reports delve into more detail for each
of the groups surveyed.

Read CPFF Oxygen Access in Canada Reports

Clinical Trials

Find resources about clinical trials.

Pulmonary Fibrosis Organization has a Clinical Trial Finder for pulmonary fibrosis related to conditions https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world

The Center for Information and Study on Clinical Research Participation (CISCRP)

Informing patients and families about clinical research: The Center for Information and Study on Clinical Research Participation’s (CISCRP) core mission is to provide accessible, relevant, useful, high quality educational resources, programs, and services that increase awareness and understanding of the clinical research process; recognize and appreciate the unprecedented gift of participation in clinical trials; enhance and enrich the participation experience for patients and their families; and promote engagement and partnership between clinical research professionals, patients, and the public. https://www.ciscrp.org/

Clinical Trials and Drug Safety In Canada

or download the pdf file.

Clinical Trials: An Overview (Video)

Todd Georgieff provides us with a detailed, easy-to-understand, walk-through of clinical trials and how they work. Learn about the different types of clinical trials, why we need them, their key aspects, recent innovations, and how to find them.

Unfortunately, clinical trials to participate in can be difficult to find. Most often, trials are offered by the clinics or hospitals that choose to participate, so it may be worth asking if there are available clinical trials that may be an option for you. Because PF trials tend to involve smaller numbers of patients from many countries, the number of places that sponsors use can also be small.

There are a couple of websites where it is possible to search for clinical trials for pulmonary fibrosis

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world:

The PF Foundation clinical trials education centre from the United States offers a clinical trial finder and more

FIBRONEER-IPF: A Phase 3 Clinical Trial – Dr. Donald Zoz

This presentation, led by Dr. Donald Zoz MD, senior clinical program leader at Boehringer Ingelheim, provides some insight into FIBRONEER-IPF, a Phase 3 Clinical Trial. The goal of FIBRONEER-IPF Phase 3 Clinical Trial is to evaluate the efficacy, safety, and tolerability of the compound BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF).

Collaborate with CPFF

Are you a med student, physician, or other professional interested in collaborating on a project focusing on pulmonary fibrosis? As Canada’s only national foundation dedicated to PF-focused research, we want to meet you! Please get in touch with us to discuss how we can work together.


1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. AmJ Respir Crit Care Med. 2002;165(2):277–304. Sourced from Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement published by Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, September 2018.